We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $875B
1-Year Est. Return 40.91%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JELD icon
10626
CALL
JELD-WEN Holding
JELD
$167M
$194K ﹤0.01%
13,300
-3,800
-22% -$69K
VRNA
10627
CALL
DELISTED
Verona Pharma
VRNA
$194K ﹤0.01%
46,200
+31,300
+210% +$134K
COOLU
10628
DELISTED
Corner Growth Acquisition Corp. Unit
COOLU
$194K ﹤0.01%
19,625
CYXT
10629
PUT
DELISTED
Cyxtera Technologies, Inc. Class A Common Stock
CYXT
$194K ﹤0.01%
17,100
-26,600
-61% -$343K
SPI
10630
CALL
DELISTED
SPI Energy Co., Ltd. Ordinary Shares
SPI
$194K ﹤0.01%
112,400
+20,700
+23% +$44.2K
ALGS icon
10631
Aligos Therapeutics
ALGS
$43M
$193K ﹤0.01%
6,358
+5,465
+612% +$186K
ATNM icon
10632
PUT
Actinium Pharmaceuticals
ATNM
$32.6M
$193K ﹤0.01%
40,100
+14,200
+55% +$80.6K
FLL icon
10633
Full House Resorts
FLL
$81.7M
$193K ﹤0.01%
31,705
-26,117
-45% -$201K
HONE
10634
PUT
DELISTED
HarborOne Bancorp
HONE
$193K ﹤0.01%
+14,000
New +$193K
NIU
10635
PUT
Niu Technologies
NIU
$163M
$193K ﹤0.01%
22,400
-1,300
-5% -$11K
PRTK
10636
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$193K ﹤0.01%
99,862
-11,160
-10% -$24.4K
DCT
10637
DELISTED
Duck Creek Technologies, Inc. Common Stock
DCT
$193K ﹤0.01%
12,991
-37,154
-74% -$653K
AVIR icon
10638
PUT
Atea Pharmaceuticals
AVIR
$411M
$192K ﹤0.01%
27,000
-148,200
-85% -$1.01M
CINT icon
10639
CI&T Inc
CINT
$469M
$192K ﹤0.01%
+19,113
New +$267K
GRTX
10640
CALL
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$192K ﹤0.01%
147,400
+23,600
+19% +$40.4K
SUMO
10641
CALL
DELISTED
Sumo Logic, Inc. Common Stock
SUMO
$192K ﹤0.01%
25,700
-24,800
-49% -$217K
PAK
10642
DELISTED
Global X MSCI Pakistan ETF
PAK
$192K ﹤0.01%
+10,700
New +$220K
ANNX icon
10643
PUT
Annexon
ANNX
$1B
$191K ﹤0.01%
+50,700
New +$155K
TV icon
10644
Televisa
TV
$1.53B
$191K ﹤0.01%
23,391
-8,222
-26% -$77.6K
MMAT
10645
PUT
DELISTED
Meta Materials Inc. Common Stock
MMAT
$191K ﹤0.01%
1,857
+574
+45% +$85.7K
LYLT
10646
PUT
DELISTED
Loyalty Ventures Inc. Common Stock
LYLT
$191K ﹤0.01%
53,360
+7,160
+15% +$76.6K
HIBS icon
10647
PUT
Direxion Daily S&P 500 High Beta Bear 3X ETF
HIBS
$17.4M
$190K ﹤0.01%
+148
New +$155K
HYFT
10648
MindWalk Holdings
HYFT
$66.3M
$190K ﹤0.01%
+49,162
New +$248K
KRON
10649
CALL
DELISTED
Kronos Bio
KRON
$190K ﹤0.01%
52,200
+800
+2% +$3.63K
NRGV icon
10650
CALL
Energy Vault
NRGV
$687M
$190K ﹤0.01%
19,000
-69,800
-79% -$907K

Similar funds

Ken Griffin's Q2 2022 Portfolio in Review

As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.